Nanopass Technologies Ltd

NanoPass is where cutting-edge technology intersects with healthcare innovation. We pioneer revolutionary solutions in intradermal delivery, reshaping the landscape of therapeutic and medical aesthetic procedures using our proprietary technology towards a precise, safe, and efficient future. Our MicronJet™ intradermal delivery product platform has redefined the standard of care. Join the Intradermal precision revolution! NanoPass's IP-backed product, the MicronJet (registered with the US FDA, the EU, Brazil, China, Australia and other countries), is the most advanced hollow microneedles device available today. Its excellent performance is backed by more than 50 clinical studies. The Company has concluded the world's first intradermal pandemic flu vaccine study and additional seasonal flu studies, demonstrating equivalent or superior immunogenicity to standard delivery using only 20% of the dose. The company is backed by prominent Israeli and US investors Ă˝and medical device companies, including IHCV, Ofer Hi-Tech, D-Partners, WFD Ventures and Elcam Medical. NanoPass recently closed a new round of financing, led by Israel Health Care Ventures (IHCV) NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.